Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with type 2 diabetes mellitus~* 6.5% ≤ HbA1c \< 9.0%~* Stopped treatment of sulfonylurea and biguanide for more than 8 weeks~* Stopped treatment of other anti-diabetic agents for more than 12 weeks~* 16 kg/m2 ≤ body mass index \< 30 kg/m2~Exclusion Criteria:~* Fasting glucose ≥ 200 mg/dL~* Required insulin therapy~* Patients with neuropathy, retinopathy or renopathy~* Contraindicated for mitiglinide or sitagliptin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: ACTIVE_COMPARATOR): None
- Mitiglinide (Type: ACTIVE_COMPARATOR): None
- Sitagliptin + Mitiglinide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).